Varda Raises $251 Million at a $1.6 Billion Valuation to Scale Drug Manufacturing in Orbit

What happened

Varda Space Industries, a company that processes pharmaceuticals in orbit, raised $251 million in a Series D round earlier this week. Reuters reported the financing on Sept. 30, and BioSpace covered it on Oct. 2. The round was co-led by Lux Capital and Natural Capital and values the company at $1.6 billion.

The financing brings Varda’s total funding to $598 million since its founding in 2021, according to BioSpace.

Company and round details

• Amount: $251 million Series D.
• Leads: Lux Capital and Natural Capital.
• Valuation: $1.6 billion.
• Total raised: $598 million.
• Founders: Will Bruey, a former SpaceX engineer, and Delian Asparouhov, a partner at Founders Fund.

Varda’s capsules launch on commercial rockets such as SpaceX’s Falcon 9, process pharmaceuticals in orbit, return to Earth and are recovered for analysis. The company’s first mission launched in 2023, and it has completed six successful reentries. It has booked 28 launches with SpaceX and other providers for 2027 through 2029.

In May 2026, United Therapeutics agreed to work with Varda on improved formulations of treatments for rare lung diseases. BioSpace did not report how the new funding will be allocated.

Lux Capital partner Shahin Farshchi called Varda “the first and only company delivering a real cadence of launches and reentries.”

Why it matters for the sector

Many drugs, particularly small molecules and some biologics, are formulated as crystals, and the form a crystal takes can affect how well a drug dissolves, how stable it is and how much reaches the bloodstream. In microgravity, the absence of convection and sedimentation can change how crystals grow. Varda’s premise is that certain forms produced in orbit may be difficult or impossible to make on Earth and could improve existing medicines or enable new formulations.

The model has moved from concept toward routine operations as launch costs have fallen and commercial reentry capability has developed. Six recoveries and a schedule of 28 booked launches suggest Varda is trying to establish a regular manufacturing cadence rather than one-off experiments.

The pharmaceutical opportunity depends on demonstrating a clear benefit that justifies the cost and regulatory complexity of space-produced materials. Partnerships with drug developers such as United Therapeutics are an early test of that proposition, and regulators will need to evaluate how manufacturing in orbit fits into existing quality and inspection frameworks.

The raise is also an example of investors funding companies at the intersection of healthcare and other industries. Varda’s backers include firms known for deep-technology and aerospace investments, and the company’s valuation reflects expectations about both its manufacturing platform and its reentry technology.

For the drug industry, novel manufacturing methods can extend the commercial life of established products through improved formulations, a strategy companies often use as patents approach expiration.

Investors will also be watching whether the economics of orbital manufacturing improve as launch frequency increases. Each mission involves launch, in-orbit processing, reentry and recovery, and the company’s ability to lower the cost per mission will influence how many pharmaceutical applications are commercially viable.

A valuation of $1.6 billion places Varda among the more highly valued companies working at the boundary of space technology and life sciences.

What to watch

• Results from the United Therapeutics collaboration on rare lung disease formulations.
• New pharmaceutical partners signing on for orbital processing.
• The cadence of launches and reentries against the 2027 to 2029 schedule.
• Regulatory guidance on drug materials manufactured in space.

Sources: BioSpace

Why Crystal Form Matters So Much in Medicine

Many drug molecules can pack together in more than one crystalline arrangement, a property known as polymorphism. The molecule is chemically identical in each form, but the different arrangements can behave very differently.

• Solubility. Some forms dissolve faster or more completely, affecting how much drug reaches the bloodstream.
• Stability. Some forms are more likely to change over time or under heat and humidity.
• Manufacturability. Crystal size and shape influence how powders flow, compress into tablets or stay suspended in injectable formulations.

The industry learned how much this matters in the late 1990s, when a previously unknown and less soluble crystal form of the HIV drug ritonavir appeared during manufacturing, forcing the original capsule to be reformulated. Episodes like that are why drugmakers invest heavily in understanding and controlling crystal forms.

What Changes in Microgravity

On Earth, gravity drives two effects that shape how crystals grow from a solution. Warmer or less dense fluid rises and cooler or denser fluid sinks, creating currents known as convection. Growing crystals also tend to settle to the bottom of a container. In orbit, both effects are largely absent. Molecules move to the growing crystal mainly by diffusion, which can lead to slower, more uniform growth. The hypothesis is that these conditions can yield crystals that are more uniform in size or that take forms difficult to produce reliably on the ground.

The Mission Cycle, Step by Step

1. Preparation. Drug materials and processing equipment are loaded into a capsule under controlled conditions.
2. Launch. The capsule rides to orbit on a commercial rocket alongside other payloads.
3. Processing. In microgravity, the planned crystallization or formulation steps take place, often with temperatures carefully controlled.
4. Reentry. The capsule returns through the atmosphere, protected by a heat shield.
5. Recovery and analysis. The capsule is retrieved and the material is analyzed to confirm its properties.

Questions Readers Ask

Would a space-made drug need special approval?

Any drug material must meet regulatory manufacturing and quality standards. How inspections and quality controls apply to processing in orbit is one of the open questions for regulators and companies.

Would patients notice a difference?

If an improved formulation works as hoped, patients might see benefits such as a different dosing method or more consistent absorption. Any change would first need to be demonstrated in testing.

Why does launch cadence matter?

Drugmakers need reliable, repeatable supply. Frequent, predictable missions are essential if orbital processing is to move beyond experiments.

Does a whole drug supply need to be made in orbit?

Not necessarily. One idea discussed in the field is to produce small amounts of a valuable crystal form in space that could then help guide or seed production on Earth, though how practical that proves will depend on the specific drug and on testing.

Who benefits first?

Likely drugmakers with established products whose formulation could be meaningfully improved, since the benefit can be measured against a known baseline.

This article is for general information only and is not investment advice.